Kymera Discloses New KT-474 Clinical Data, Unveils New
Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of...
Source: globenewswire.com
Page 9 - Multiple Ascending Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multiple Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multiple Ascending Dose Today - Breaking & Trending Today
TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
-- Company to host key opinion leader webinar today, October 1, at 10:00am ET --LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing
Source: finanznachrichten.de
Investegate |Amolyt Pharma Announcements | Amolyt Pharma: Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
Investegate announcements from Amolyt Pharma, Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting
Source: investegate.co.uk
Larimar Therapeutics Reports First Quarter 2021 Operating
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results May 10, 2021 16:05 ET | Source: Larimar Therapeutics Larimar Therapeutics Bala Cynwyd, UNITED STATES - Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a c...
Source: globenewswire.com